Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : AVANT Immunotherapeutics Inc. (Nasdaq: AVAN) -- Ignore unavailable to you. Want to Upgrade?

To: rrufff who wrote (422)	11/4/2002 6:47:28 PM
From: SemiBull	Read Replies (1) \| Respond to of 513

AVANT CEO to Present at The Wall Street Analyst Forum on November 11, 2002 Monday November 4, 11:01 am ET NEEDHAM, Mass.--(BUSINESS WIRE)--Nov. 4, 2002--AVANT Immunotherapeutics, Inc. (Nasdaq: AVAN - News) today announced that company President and CEO Una S. Ryan, Ph.D., will make a presentation to analysts and portfolio managers at The Wall Street Analyst Forum's Institutional Investors Conference on Monday, November 11, 2002 at 11:40 a.m. Eastern time. The meeting is being held at The Roosevelt Hotel in New York City. A live webcast of the 40-minute presentation will be available online via the Investor Information area of AVANT's website at avantimmune.com and at media.corporate-ir.net media_files/Event/2002/nov/wsaf/111102.htm. An archive of the webcast will be available via AVANT's website for 14 days following the event. AVANT Immunotherapeutics, Inc. is engaged in the discovery, development and commercialization of products that harness the human immune system to prevent and treat disease. The company is developing a broad portfolio of vaccines against viral and bacterial diseases, including single-dose oral vaccines. In addition, the company is conducting clinical studies of a proprietary vaccine candidate for cholesterol management. AVANT further leverages the value of its technology portfolio through corporate partnerships. Current collaborations encompass the development of an oral human rotavirus vaccine, vaccines to combat threats of biological warfare, and vaccines addressed to human food safety and animal health. Additional information on AVANT Immunotherapeutics, Inc. can be obtained through our site on the World Wide Web: avantimmune.com. -------------------------------------------------------------------------------- Contact: AVANT Immunotherapeutics, Inc. Una S. Ryan, Ph.D., 781/433-0771 or AVANT Immunotherapeutics, Inc. Avery W. Catlin, 781/433-0771 info@avantimmune.com or For Media: Kureczka/Martin Associates Joan Kureczka/Jesse Fisher, 415/821-2413 jkureczka@aol.com -------------------------------------------------------------------------------- Source: AVANT Immunotherapeutics, Inc.